Commonwealth Bank of Australia boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 7.5% in the second quarter, Holdings Channel reports. The fund owned 766,778 shares of the biopharmaceutical company’s stock after acquiring an additional 53,420 shares during the period. Commonwealth Bank of Australia’s holdings in Pfizer were worth $27,814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently added to or reduced their stakes in PFE. W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in shares of Pfizer during the first quarter valued at about $132,000. Braun Bostich & Associates Inc. acquired a new position in shares of Pfizer during the first quarter valued at about $139,000. Clearwater Capital Advisors LLC acquired a new position in shares of Pfizer during the first quarter valued at about $156,000. Goodwin Daniel L acquired a new position in shares of Pfizer during the second quarter valued at about $171,000. Finally, Bristol John W & Co. Inc. NY acquired a new position in shares of Pfizer during the first quarter valued at about $186,000. 68.64% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer stock opened at $43.14 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. The stock has a market cap of $256.57 billion, a price-to-earnings ratio of 16.28, a PEG ratio of 2.15 and a beta of 0.88. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $45.81.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be paid a dividend of $0.34 per share. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.15%. Pfizer’s dividend payout ratio is 51.32%.
A number of brokerages have recently commented on PFE. Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, August 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, July 31st. Goldman Sachs Group reaffirmed a “neutral” rating and set a $42.00 price objective on shares of Pfizer in a research report on Wednesday, August 1st. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Finally, Deutsche Bank set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $42.67.
In other news, major shareholder Pfizer Inc acquired 55,556 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the purchase, the insider now owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was posted by WKRB News and is the property of of WKRB News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.wkrb13.com/2018/11/24/pfizer-inc-pfe-shares-bought-by-commonwealth-bank-of-australia.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: What Factors Can Affect Return on Equity?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.